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Abstract Novel substances of expected doping activity are
constantly introduced to the market. β-Methylphenethylamine
(BMPEA) is classified as a doping agent by the World Anti-
Doping Agency as it is a positional isomer of amphetamine. In
this work, the development and application of a simple and
rapid analytical procedure that enables discrimination between
both isomers is described. The analytes of interest were extract-
ed from urine by a two-step liquid–liquid extraction and then
analyzed by UPLC/MS/MS under isocratic conditions. The
entire analytical procedure was validated by evaluating its
selectivity, discrimination capabilities, carry-over, sensitivity,
and influence of matrix effects on its performance. Application
of the method resulted in detection of BMPEA in eight anti-
doping samples, including the first report of adverse analytical
finding regarding its use. Further analysis showed that BMPEA
may be eliminated unchanged along with its phase II conju-
gates, the hydrolysis of which may considerably improve de-
tection capabilities of the method. Omission of the hydrolysis
step may therefore, produce false-negative results. Testing lab-
oratories should also carefully examine their LC/MS/MS-based
amphetamine and BMPEA findings as both isomers fragment
yielding comparable collision-induced dissociation spectra and
their insufficient chromatographic separation may result in
misidentification. This is of great importance in case of forensic
analyses as BMPEA is not controlled by the public law, and its
manufacturing, distribution, and use are legal.
Keywords Stimulant . Amphetamine isomer . Liquid
chromatography .Mass spectrometry . Doping . Sport
Introduction
In recent years, new doping substances have been" continuous-
ly introduced to the market in the form of nutritional supple-
ments. They are often produced in clandestine drug laboratories
bymodification or positional rearrangement of well-established
doping agents such as stimulants [1–3]. The main aim of these
activities is to deliver specifically designed, biologically active
substances which are not controlled by the public law. This
allows for making a profit on selling a product yielding “un-
precedented results” that, in the case of stimulating agents,
would correspond to such effects as rapid weight loss or the
ability to perform extensive training for extended periods of
time. The presence of designer substances in these products
usually remains unknown until anti-doping laboratories identi-
fy them [1, 4–6]. This, in turn, may lead to a large number of
sanctioned athletes that fail anti-doping tests once testing lab-
oratories have implemented methods for their detection. This is
due to the fact that the list of substances prohibited in sport is
open and defines novel doping agents based on their similarity
in action and/or structure to those already listed [7, 8]. One of
the recent examples is 1,3-dimethylamylamine [9, 10], an
isomer of the stimulant tuaminoheptane.
Athletes invariably claim that they were unaware of the
presence of new designer stimulants in the supplements they
have used. In fact, these agents are often not listed in the
nutrition fact labels, or even if they are, their chemical names
are either altered or are too difficult for a non-chemist to
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identify them. In the case of 1,3-dimethylamylamine, the
labels listed either its synonyms (37 deposited in the
PubChem database [11]) or named geranium oil or geranium
extract as its source. Although a notion that this substance was
added to nutritional supplements in a form of synthetic mate-
rial seems to predominate, there is still an intense debate
whether or not these extracts indeed contain 1,3-
dimethylamylamine [12–15]. The mechanism of action of
newly designed substances is usually unknown; they are
simply expected to have a similar biological effect to the
template substance of desired activity [2, 3]. As such, they
may pose a serious threat to public health, and e.g., death cases
having possible associations with 1,3-dimethylamylamine use
have already been reported [16]. Forensic analyses performed
in relation to such fatal accidents must unequivocally identify
the substance that may have been abused or ingested by the
deceased. This, in turn, allows for legal actions to be taken
against the manufacturers or distributors. However, this is
mostly the case when these substances are listed as controlled
by the government. It is also noteworthy that returning an
adverse finding related to inadvertent doping may have detri-
mental effects on the mental balance of professional athletes,
especially those that are rather risk avoiders and value their
health over the medal winning [17].
β-methylphenethylamine (BMPEA) is a novel additive of
expected stimulant activity found in nutritional supplements.
It is a positional isomer of amphetamine, and based on this
structural similarity, it is classified as a stimulant by the World
Anti-Doping Agency (WADA) [7]. Detection of BMPEA or
amphetamine in a urine sample collected in competition con-
stitutes a doping offense and results in sanctions against the
athlete. In the forensic field, however, unequivocal identifica-
tion of amphetamine in a mixture of its positional isomers and
structurally related compounds is of critical importance; the
latter substances are often not controlled by the public law,
and their manufacturing, distribution, and use are legal.
The aim of this work was to elaborate an ultra-performance
liquid chromatography–tandem mass spectrometric
(UPLC/MS/MS) analytical procedure enabling discrimination
between amphetamine and BMPEA. The described method
was successfully applied to anti-doping urine samples and led




The standards of pure substances amphetamine, β-
methylphenethylamine (1-amino-2-phenylpropane), and
phentermine were purchased from Sigma-Aldrich (Poland).
Hydrochloric acid, potassium hydroxide, sodium sulfate, and
boric acid were obtained from POCH (Poland). L-Cysteine,
tert-butanol, and LC/MS-grade methanol were purchased
from Merck Millipore (Germany). Diethyl ether and formic
acid were from J.T.Baker (Holland), whereas methyl tert-
butyl ether (MTBE) was purchased from Rathburn
(Scotland). The Millipore DirectQ UV3 system (R>18 MΩ/
cm, Germany) was used as the source of water.
Stock solutions of standard substances were prepared at the
concentration of 1 mg/ml in methanol and stored at −20 °C.
Working solutions were prepared in methanol at the concen-
trations of 10 ng/ml, 1 μg/ml, or 100 μg/ml and were stored at
4 °C.
Sample preparation
Samples were prepared according to the procedure described
previously [18] with modifications. Briefly, 1 ml of urine was
diluted with 4 ml of water and subsequently spiked with 50 μl
of phentermine at 1 μg/ml (internal standard). After an addi-
tion of 1 ml of 6 mol/l HCl and approx. 100 mg of L-cysteine
(antioxidant), samples were incubated at 105 °C for 30 min
and cooled down to room temperature afterwards. Next, ex-
traction with 5 ml of diethyl ether was performed (20 min) in
order to remove acidic interferences. Samples were then cen-
trifuged (5min/3,000 rpm), and the ether phase was discarded.
The pH of aqueous phase was adjusted to 9–10 with 1 ml of
10 mol/l borate buffer, and this was followed by the addition
of 500 μl of tert-butanol, approx. 3 g of anhydrous sodium
sulfate, and 5 ml of MTBE. Samples were then shaken and
centrifuged, and the organic layer was recovered and evapo-
rated under a nitrogen flow at 55 °C. The dry residue was
reconstituted in 1 ml of methanol/H2O mixture (v/v, 2:8).
Injection volume was fixed at 5 μl.
To assess whether conjugate hydrolysis improves the meth-
od performance, excretion samples were spiked with amphet-
amine at 300 ng/ml (internal standard) and prepared in dupli-
cates according to the protocol described above with one
exception: one sample of each duplicate was kept in a heat
block for 30 min without the addition of acid in order to
considerably shorten the duration of hydrolysis. Afterwards,
the samples were cooled down to room temperature, and 1 ml
of 6 mol/l HCl was added to reproduce the extraction condi-
tions of the cleanup step.
Chromatographic separation
Chromatographic separation was achieved on a Waters
Acquity UPLC system equipped with an HSS T3 column
(100 mm×2.1 mm, 1.7 μm; Waters, USA). The mobile phase
consisted of 0.1 % formic acid in water (A) and 0.1 % formic
acid in methanol (B), and the flow rate was 300 μl/min at
45 °C. The initial B concentration of 10 % was constant over
7.5 min to resolve the isomers. Next, it increased to 100 % in
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1 min and then was held for additional 0.5 min. The column
was re-equilibrated with the mobile phase of the initial com-
position for 1.5 min. Samples were stored at 4 °C in an
autosampler prior to analysis.
Mass spectrometry conditions
The studied substances were traced in a multiple reaction
monitoring (MRM) mode with a Micromass Quattro Premier
XE (Waters, USA) mass spectrometer equipped in an
electrospray ionization (ESI) source. The desolvation gas flow
was set at 800 l/h and 300 °C, and the source temperature was
120 °C. The capillary voltage applied was 2.0 kV. The cone
and collision gas flows were set at 50 l/h and 0.35 ml/min,
respectively. Dwell time was set at 0.01 s. Amphetamine and
BMPEAwere traced at the cone voltage (CV) set at 20 V with
the following selected precursor ion–product ion transitions at
their respective collision energies (CE): m/z 136.11>65.04,
CE 35 eV; 136.11>91.05, CE 20 eV; and 136.11>119.09, CE
10 eV. To monitor phentermine, the 150.13>91.05 transition
was used at the CVand CE set at 25 Vand 25 eV, respectively.
Collision-induced dissociation spectra were obtained with
aMicromass QToF Premier mass spectrometer (Waters, USA)
equipped in an ESI source. The desolvation gas flowwas set at
600 l/h and 300 °C, and the source temperature was 120 °C.
The cone and collision gas flows were set at 20 l/h and
0.15 ml/min, respectively. The system was operated in a
wide-pass quadrupole mode, and data were acquired in a W-
optics centroid mode over the range of m/z 30–300 with the
mass resolution of at least 14,000 full width at half maximum
(FWHM). The scan time was 0.5 s with the interscan delay set
at 0.02 s. The capillary and cone voltages, and collision
energies applied were set individually for every substance.
Solutions of reference substances at 100 μg/ml in H2O/meth-
anol (v/v, 1:1) were infused at the rate of 10 μl/ml in the




Method selectivity was studied by analyzing 10 different urine
specimens known to be free of amphetamine and BMPEA.
The extracted ion chromatograms at the retention times of the
studied compounds were examined for interfering peaks.
Discrimination capability and limit of detection
Identification criteria and minimum required performance
limits (MRPLs) applied for the method followed the
TD2010IDCR [19] and TD2013MRPL [20] technical docu-
ments, respectively. In order to evaluate the capability of the
method to discriminate between amphetamine and BMPEA at
different concentration levels, each of six blank urine samples
was spiked with both isomers at 10 ng/ml (0.1 MRPL),
50 ng/ml (0.5 MRPL), 250 ng/ml (2.5 MRPL), and
1,250 ng/ml (12.5 MRPL). The extracted ion chromatograms
were then inspected in order to assess whether obtained results
allowed for unequivocal identification of the substances.
Recovery, matrix effect, and process efficiency
Investigation of recovery (RE), matrix effect (ME), and pro-
cess efficiency (PE) was performed in six different urine
matrices at two concentration levels and followed the proce-
dure published by Matuszewski et al. [21] and updated by
Marchi et al. [22]. To evaluate RE, urine samples were forti-
fied with analytes at 50 ng/ml and 1,250 ng/ml and extracted
together with two blank samples for each urine. The latter
samples were then spiked with the analytes at the correspond-
ing concentrations just prior to evaporation. The RE was
calculated by the comparison of peak areas obtained for
samples fortified before and after extraction. ME was deter-
mined by dividing peak areas recorded for samples spiked
after extraction by peak areas of corresponding standard sam-
ples prepared in the mobile phase. Finally, to establish PE,
peak areas obtained for samples fortified before extraction
were compared to the peak areas of corresponding standard
samples prepared in the mobile phase. All parameters were
expressed as percentages.
Carry-over
Carry-over was evaluated by three consecutive injections of
blank samples after a sample spiked post-extraction with
analytes at 1,250 ng/ml. The analysis was performed for two
different urine samples. The presence of carry-over was eval-
uated by visual inspection of the chromatograms obtained for
blank urine samples. A ratio of peak areas of the blank sample
and the sample containing analytes was defined as satisfactory
when its value was below 0.1 %.
Application to real case samples
Following the validation, the method was routinely used to
confirm the presence of amphetamine and BMPEA in
suspected anti-doping samples. Four samples found positive
for BMPEAwere subsequently used to evaluate the impact of
glucuronide and sulfate deconjugation on the method perfor-
mance. Samples were prepared in duplicates with the addition
of amphetamine at 300 ng/ml (internal standard), and one
sample for each duplicate was hydrolyzed for a shorter time.
Concentrations of BMPEAwere calculated by comparing the
peak areas of BMPEA and amphetamine in a given sample.
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Dilute-and-shoot analysis
Samples were prepared as follows: 500 μl of urine was
diluted with 500 μl of water and then spiked with 10 μl of
phentermine at 10 μg/ml as the internal standard. Samples
were briefly vortexed and centrifuged (5 min/3,000 rpm),
and 100 μl was transferred to vials afterwards. Injection
volume was fixed at 10 μl. Selectivity was determined by
the analysis of 20 urine samples that had been deemed
negative in the routine anti-doping screening. Limits of
detection were established in 10 different urines, each
spiked with amphetamine and BMPEA at 10 or
50 ng/ml. For analysis of excretion samples, amphetamine
(final concentration, 300 ng/ml) was used as an internal
standard both to quantify BMPEA and to correct for
considerable variations in the BMPEA retention time
caused by the matrix components. The analysis of excre-
tion samples was repeated three times.
Results and discussion
A growingmarket of designer stimulants leads to the detection
of such new compounds by anti-doping laboratories almost
every year. As these substances are often functional and/or
structural analogs of already known doping agents, their use
by an athlete in sport competitions constitutes a doping of-
fense. In respect of the detection methodology, structural
analogs often exhibit patterns of collision-induced dissocia-
tion (CID) and retention times comparable with those of well-
established stimulants. This, in turn, gives anti-doping labo-
ratories a possibility to identify them even in directed screen-
ing procedures.
Development of confirmatory method
Initial analysis of a received urine sample followed
screening procedures for in-competition testing. An in-
tense signal was observed in the chromatogram of am-
phetamine (MRM 136.11>91.05) from the UPLC/MS/MS
screening for stimulants and narcotics. In this case, how-
ever, the athlete declared the use of the No-shotgun nu-
tritional supplement which had BMPEA listed as an ad-
ditive in the nutrition label. As amphetamine and BMPEA
are positional isomers, it was important to evaluate their
fragmentation patterns. The CID spectra were obtained by
using the high-resolution time-of-flight technology (at
least 14000 FWHM) and showed that both compounds
fragmented into ions of the same m/z values (Fig. 1)
which hampered their possible direct discrimination.
Therefore, amphetamine and BMPEA needed to be re-
solved chromatographically for their unequivocal identifi-
cation. Several different columns, mobile phases, and
gradients were tested (not shown), and the best results
were obtained with isocratic separation (0.1 % formic acid
in methanol/0.1 % formic acid in water, v/v, 1/9) per-
formed on an HSS T3 column (Fig. 2). Performance of
the method was subsequently evaluated in compliance
with the International Standard for Laboratories and
EURACHEM guidelines [23, 24].
Method validation
Selectivity
Selectivity of the method was assessed by the analysis of
10 blank urines. Evaluation of chromatograms recorded
for three selected precursor ion-product ion transitions at
the retention times of amphetamine and BMPEA
(±1.0 min) showed the absence of any interfering compo-
nents. It is also important to note that the sample prepa-
ration protocol of the confirmatory method was developed
(with minor modifications) based on a highly selective
screening procedure for amphetamine that had been used
for analysis of at least a few thousands of samples. The
sole drawback of the screening procedure in relation to
the data presented here is the lack of BMPEA and am-
phetamine chromatographic separation. To provide addi-
tional information on the selectivity of the confirmatory
method, 20 routine screening samples that had been
deemed negative were additionally tested. Analysis of
obtained chromatograms showed no interfering peaks
even though the screening samples were approx. 33 times
more concentrated than those prepared for confirmatory
analysis. This data indicates that the developed method is
highly selective for determining the presence of amphet-
amine and BMPEA in urine.
Discrimination capability and limit of detection
The capability of the method to discriminate between
amphetamine and BMPEA at different concentrations
was evaluated by the analysis of six blank urine samples
spiked with these substances at four different levels:
10 ng/ml (0.1 MRPL), 50 ng/ml (0.5 MRPL), 250 ng/ml
(2.5 MRPL), and 1,250 ng/ml (12.5 MRPL). This range
was chosen based on our experience with amphetamine
findings in routine anti-doping testing as well as in order
to meet the WADA requirements concerning detection of
stimulants in urine [20]. As shown in Fig. 2A, the method
allowed for differentiation between amphetamine and
BMPEA within the tested concentration range. LODs for
both compounds were established at 10 ng/ml as it was
the lowest concentration targeted in validation. Owing to
the fact that anti-doping laboratories should not report the
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presence of stimulants in urine samples below 50 ng/ml
[20], this was deemed satisfactory.
Recovery, matrix effect, and process efficiency
Recovery (RE), matrix effect (ME), and process efficiency
(PE) were determined at two concentration levels in six dif-
ferent urine matrices on two different days. As shown in
Table 1, RE, ME, and PE values were similar for amphet-
amine and BMPEA. Interestingly, the observed PE values
close to 100 % are a result of antagonistic effects of low
REs and signal enhancement (positive influence of matrix
on the ionization process). The latter phenomenon is rather
rarely observed in ESI-based analyses, as this technique is
known to lead mostly to signal suppression [22]. As signal
enhancement was found in all matrices tested, it is likely
caused by residual compounds of endogenous origin. Impor-
tantly, variability of matrix effects (SDME) established for the
six individual matrices is close to 15 % (Table 1), the accept-
able limit for this parameter [25]. Owing to the fact that RE,
ME, and PE parameters for amphetamine and BMPEA are
comparable, it is possible to use amphetamine as the internal
standard for BMPEA quantitation in urine and vice versa.
Carry-over
Carry-over was evaluated by injection of three blank urine
samples directly after samples spiked post-extraction with
amphetamine and BMPEA at 1,250 ng/ml. Visual inspection
of chromatograms of the blank urines revealed no noticeable
carry-over (<0.1 %).
Application to real case samples
Application of the developed procedure resulted in the iden-
tification of BMPEA in the suspected sample (data not
shown), and consequently, the first case of BMPEA doping
was reported (2010). Additionally, the method of chromato-
graphic separation allowed for the detection of BMPEA in the
No-shotgun supplement, in which it was estimated to be
present at approx. 770 μg/g (16 mg per serving; our unpub-
lished results). Afterwards, all urine samples suspected for
amphetamine/BMPEA were routinely analyzed by the
Fig. 1 ToF MS/MS spectra for the m/z 136.11 precursor ions of amphetamine (a) and BMPEA (b)
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described method revealing additional seven cases of doping
with BMPEA.
To provide the first insights in the process of BMPEA
excretion, four real case samples were used to investigate the
influence of hydrolysis of phase II metabolic conjugates on
method performance. Each excretion sample was prepared in
duplicate for which one was hydrolyzed for a shorter time
(acidic hydrolysis may have occurred in these samples only
for 20 min at ambient temperature during the cleanup extrac-
tion, whereas the other samples were hydrolyzed for
additional 30 min at 105 °C). Concentrations of BMPEAwere
estimated by using amphetamine (internal standard) spiked at
300 ng/ml (Fig. 2B). The analysis showed that shortening the
duration of the hydrolysis step decreased the signal recorded
for BMPEA up to 5-fold (Table 2). This data shows that
BMPEA may be eliminated as direct conjugates, e.g., glucu-
ronides, synthesis of which bypasses the phase I metabolic
pathways. Moreover, these metabolites seem to be present in
the urine sample with high H/sH ratio (approx. 5) at much
higher levels than free BMPEA. On the other hand, longer
hydrolysis caused only a slight increase in the BMPEA con-
centrations measured in the other samples (H/sH value close
to 1; Table 2). This may indicate a negative influence of the
matrix on deconjugation efficiency and/or that unchanged
BMPEA may be more abundant in these samples than its
phase II conjugates. The latter possibility was tested by a
dilute-and-shoot approach.
Detection of free BMPEA in excretion samples
by dilute-and-shoot method
To test whether BMPEA may be eliminated in a free form,
excretion samples were analyzed by using a dilute-and-shoot
Fig. 2 Discrimination capabilities of the method at different concentra-
tion levels (a) and chromatograms of a real case sample prepared with
hydrolysis (H) or shortened hydrolysis (sH) of metabolic conjugates (b).
Amphetamine (AMPH) was used as an internal standard to quantify
BMPEA concentration in excretion urines. Extracted ion chromatograms
were recorded for the precursor ion of m/z 136.11
Table 1 Recovery (RE), matrix effect (ME), and process efficiency (PE)
parameters established for the method SDME is the standard deviation of
the ME parameter
Concentration (ng/ml) RE (%) ME (%) SDME (%) PE (%)
BMPEA
50 77.33 125.17 8.21 97.00
1,250 65.86 141.07 15.59 93.40
Amphetamine
50 77.19 120.11 9.78 92.89
1,250 64.66 139.35 13.55 90.67
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method. This procedure was demonstrated to be selective by
analysis of 20 different urine samples which revealed no
interfering peaks at the retention times of amphetamine and
BMPEA (±1.0 min; Fig. 3A). Limits of detection for both
substances were established at 10 ng/ml as this was the lowest
concentration tested (Fig. 3A). The stability of retention times
was, however, rather poor, indicating a strong influence of the
matrix on chromatographic separation (Fig. 3A, B). Thus,
amphetamine was used as the internal standard to estimate
BMPEA concentration and to correct for instability of
BMPEA retention time. The analysis showed that unchanged
BMPEA was present in all excretion samples in concentra-
tions similar to those estimated in the corresponding samples
prepared with shortened hydrolysis (Table 2, Fig. 3B). Thus,
our data indicates that BMPEA may be eliminated unchanged
and as conjugates, and that the elimination profile of BMPEA
may undergo significant changes, perhaps similar to those
already described for amphetamine [26, 27]. Additionally,
the high structure similarity between amphetamine and
BMPEA suggests that both compounds may also share some
of their phase I metabolic pathways, e.g., aromatic hydroxyl-
ation [26, 27]. This hypothesis, however, requires further
research as such putative BMPEA metabolites were not
targeted in this study.
Conclusions
The analytical procedure for discrimination of amphetamine
and BMPEA in urine samples presented here was proven to be
simple and rapid and was validated in compliance with ap-
propriate guidelines and WADA requirements. The limits of
detection were established at 10 ng/ml, and discrimination
capabilities were demonstrated to be satisfactory up to the
concentration of 1.25 μg/ml. The analytical performance re-
lated to matrix effects, recovery, and carry-over was accept-
able and very similar for both compounds, indicating that one
substance may be used as the internal standard for quantitation
of the other. The fit for purpose of the method was also
demonstrated by analysis of real case samples and resulted
in reporting of eight BMPEA doping cases. Further investiga-
tion of excretion samples provided first insights into BMPEA
metabolism and showed that it may be eliminated unchanged
and in the form of its phase II conjugates (phase I metabolites
were not targeted in this study). Interestingly, the relative
concentrations of both fractions may considerably differ in a
given sample. Consequently, omission of the hydrolysis step
may produce false-negative results, as it was shown to in-
crease BMPEA concentration even up to 5-fold. The fact that
both isomers fragment yielding comparable CID spectra
Table 2 Estimated concentra-
tions of BMPEA in excretion
samples
H hydrolysis, sH shortened
hydrolysis
aMean of two measurements
Sample Estimated concentration (ng/ml)
H/sH ratio H CV (%) sH CV (%) Dilute and shoot CV (%)
1 1.44 1,208 4.2 836 7.8 778 4.4
2 1.53 420 1.2 274 3.8 321 14.6
3 1.25 1,249 6.7 997 2.0 1,011 –a
4 5.61 881 3.7 157 4.5 158 6.5
Fig. 3 Analytical performance of the dilute-and-shoot method (a) and a chromatogram of excretion sample (b). Amphetamine (AMPH) was used as an
internal standard to quantify BMPEA concentration and to correct for matrix-dependent shifts of BMPEA retention time
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indicates that insufficient chromatographic separation may
result in misidentification. Thus, testing laboratories should
interpret their LC/MS/MS-based amphetamine and BMPEA
findings with great care. This is of utmost importance in the
forensic field as BMPEA is not controlled by the public law,
and its manufacturing, distribution, and use are legal.
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